A new method to deliver cancer treatment directly to the bladder
Official title: An urinary drug disposing approach for treatment of bladder Cancer
Funded at Weill Medical Coll of Cornell Univ · NIH-10887643 · Data updated 2026-11-12
This study is testing a new way to deliver bladder cancer treatment through an IV, which could make it easier for patients and help prevent the cancer from coming back.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 13, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $595,483 |
| NIH project number | 5R01CA276506-02 |
| Project ID | NIH-10887643 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-muscle invasive bladder cancer who are seeking alternative treatment options.
✕Less likely to help
Patients with muscle invasive bladder cancer who are eligible for radical cystectomy may not benefit from this research.
What this research studies
This research focuses on improving bladder cancer treatment by developing a new drug delivery method that addresses the limitations of current therapies. Most bladder cancer patients are treated with intravesical immunotherapy or chemotherapy, which can be invasive and often ineffective for tumors in the upper urinary tract. The study proposes using a bio-inert peptide that can be administered intravenously, allowing for better distribution of the treatment throughout the urinary system. This approach aims to enhance patient compliance and reduce recurrence rates of bladder cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective bladder cancer treatments and improved survival rates for patients.
How similar studies have gone: While this approach is innovative, similar research has shown promise in improving drug delivery methods for other types of cancers.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Law, Benedict Shek Hang — Weill Medical Coll of Cornell Univ
- Study coordinator: Law, Benedict Shek Hang
Related research
Other NIH-funded projects on the same topics.
-
Population modeling to reduce bladder cancer burden
Aimed at predicting and guiding effective, population-based ways to prevent and control bladder cancer.
-
Blocking a new immune checkpoint in bladder cancer
Researchers are trying medicines that block a newly found immune pathway to help people with bladder cancer, especially those whose tumors do not respond to current immunotherapy.
-
Nrf2 in T cells and how it could boost immune power against bladder cancer
A small grant will explore how a T-cell protein called Nrf2 affects muscle-invasive bladder cancer and whether targeting it could help patients respond better to immune therapies.
-
Understanding why bladder cancer spreads and resists treatment
This grant studies how advanced bladder cancer changes and spreads across the body, aiming to uncover why it’s hard to treat.
-
Molecular clues to bladder cancer cell changes and therapy response
This NIH grant looks at how bladder cancer cells change their identity and how that affects response to treatment, with a focus on aggressive neuroendocrine variants.
-
Repurposing spironolactone to treat bladder cancer inside the bladder
Aims to repurpose spironolactone as an intravesical treatment for non-muscle invasive bladder cancer to help prevent recurrence and progression.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.